Caroline Hopkins

Articles Authored by Caroline Hopkins
A Cambridge University study found phrases touting the benefits of genomics research without acknowledging limitations can turn off the very people researchers need to engage most.

Duke Researchers Use Veracyte Data to ID Prostate Cancer Subgroups for Added Post-Surgery Treatment
Premium
The recent JCO Precision Oncology study could bolster the research use case for Veracyte's Decipher GRID database in better defining prostate cancer subgroups.

Cofactor Quickly Moving Immunotherapy Predictive Test to Market With Data From Intermountain Spinout
Premium
Culmination Bio's 4.5 million biospecimens and longitudinal omics and clinical data may help Cofactor rapidly advance the OncoPrism assay into multiple cancer types.

An analysis of whole-exome sequencing results presented at AACR suggests many people with hereditary cancer risk variants don't fall under current NCCN guidelines.

Function Oncology Launches With $28M, Seeks to Transform Precision Cancer Therapy With CRISPR
Premium
The firm unveiled early validation data for its CRISPR-based functional genomics platform, which it hopes to commercialize as another tool doctors can use to individualize cancer care.

Biomarker Predicts Immunotherapy Benefit in Head and Neck Cancer but Commercial Path Unclear
Premium
Somatic 9p24.1 copy number alterations predicted the degree to which HPV-negative advanced squamous head and neck cancers benefitted from Keytruda and Opdivo.

Repeat Biomarker Testing Informs Next Steps for Treatment-Resistant EGFR-Mutant NSCLC Patients
Premium
Studies at ESMO showed the importance of repeat biomarker testing to guide treatment after resistance to AstraZeneca's Tagrisso, but tissue-based testing remains a hindrance.

In new guidelines, an expert panel recommended IHC and PCR for certain cancer types and pointed out knowledge gaps supporting NGS in other settings.

Agendia Building Validation Data on ImPrint for Guiding Neoadjuvant Immunotherapy in Breast Cancer
Premium
The firm envisions marketing the 53-gene signature with its existing MammaPrint and BluePrint tests as a comprehensive platform for breast cancer treatment selection.

Intermountain Healthcare Rolling Out Galleri Multi-Cancer Early Detection Test in Pilot Program
Premium
The test is first available to employees over age 50 covered under Intermountain's SelectHealth, but the health system has a bigger five-year plan.
